Skip to main content
. 2021 Jan 19;10(2):137–147. doi: 10.1002/psp4.12582

Table 2.

CPI population PBPK model parameter estimates

Parameter kSYN in blood (FLsyn = 0) kSYN in liver (FLsyn = 1)
Fixeda BSVb BOVc Fixeda BSVb BOVc
System parameter
ksyn, nMol/h 18.4 (11) 10 (30) 33.1 (12) 7.3 (87)
CLB, L/h 6.24 (24) 38.2 (23) 34.4 (21) 5.28 (8) 16 (28) 14.2 (16)
CLR, L/h 2.7 (6) 12.7 (30) 2.7 (6) 13.5 (28)
VC, L 11.9 (21) 25.8 (29) 13 (16) 24.9 (29)
CLactive,0, L/h 1397 (32) 930 (15)
Ki, μM 0.93 (7) 1.44 (10)
Covariates
FRAX 0.269 (13) 0.486 (13)
COVGEN d 0.788 0.673
COVRACE 0.417 (18) 0.323 (16)
COVSEX 0.232 (24) 0.26 (21)
Residual unexplained variabilities
σprop (%) – plasma 13.2 (5) 13.3 (5)
σadd, nM – plasma 0.001 FIXED 0.001 FIXED
σprop (%) – urine 34.8 (8) 34.9 (8)
σadd, nMol – urine 2.3 (50) 2.18 (59)

σprop, proportional residual error; σadd, additive residual error; BOV, between occasion variability; BSV, between subject variability; CLB, biliary clearance; CLR, renal clearance; CLuptake,0, hepatic active uptake clearance (CLactive,u) in white men with SLCO1B1 521TT genotype; COVGEN, fractional change in CLactive,u in SLCO1B1 521CC genotype; COVRACE, fractional change in CLactive,u in Asian‐Indian subjectss; COVsex, fractional change in ksyn in women relative to men; CPI, coproporphyrin I; FLsyn, fraction CPI synthesis in the liver; FRAX, surrogate variable of genetic effect; Ki, total rifampicin OATP1B1 inhibition constant (equivalent to 0.10 µM as unbound K i calculated with rifampicin fu,p of 0.11); ksyn, rate of coproporphyrin I synthesis; PBPK, physiologically‐based pharmacokinetic; Vc, volume of blood (central) compartment.

aThe population (fixed effect) parameters. Values within parentheses represent relative standard errors (RSE, %). bEstimated BSV (%) and its RSE (%). cEstimated BOV (%) and its RSE (%). dCalculated based on the population (fixed effect) parameter estimate of FRAX.